SUNItinib malate 12.5 mg Oral Capsule
RxNorm 616279
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 616279 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: Sunitsinib malate 12.5 mg Oral Capsule.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
Semantic Clinical Drug (SCD):
Sunitinib 12.5 mg Oral Capsule
(Atom ID: 2404134)
Full form of descriptor (FN):
Product containing precisely sunitinib (as sunitinib malate) 12.5 mg/1 each conventional release oral capsule (clinical drug)
(Atom ID: 10317459)
Designated preferred name (PT):
Sunitinib (as sunitinib malate) 12.5 mg oral capsule
(Atom ID: 10321273)
Synonym (SY):
Sunitinib 12.5 mg (as sunitinib malate 16.7 mg) Oral Capsule
(Atom ID: 12511123)
Tall Man Lettering Synonym (TMSY):
SUNItinib 12.5 mg (as SUNItinib malate 16.7 mg) Oral Capsule
(Atom ID: 12511954)
Tall Man Lettering Synonym (TMSY):
SUNItinib 12.5 mg Oral Capsule
(Atom ID: 3732233)
Prescribable Name (PSN):
SUNItinib malate 12.5 mg Oral Capsule
(Atom ID: 6365822)
Patient Education
Sunitinib
Sunitinib is used to treat gastrointestinal stromal tumors (GIST; a type of tumor that grows in the stomach, intestine (bowel), or esophagus (tube that connects the throat with the stomach) in people with tumors that were not treated successfully with imatinib (Gleevec) or people who cannot take imatinib. Sunitinib is also used to treat advanced renal cell carcinoma (RCC, a type of cancer that begins in the cells of the kidneys). Sunitinib is also used to help prevent the return of RCC in people who have RCC that has not spread and have had a kidney removed. Sunitinib is also used to treat pancreatic neuroendocrine tumors (pNET, a type of tumor that begins in certain cells of the pancreas) in people with tumors that have worsened and cannot be treated with surgery. Sunitinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells and may help shrink tumors.
[Learn More]
Cancer Chemotherapy
Normally, your cells grow and die in a controlled way. Cancer cells keep growing without control. Chemotherapy is drug therapy for cancer. It works by killing the cancer cells, stopping them from spreading, or slowing their growth. However, it can also harm healthy cells, which causes side effects.
You may have a lot of side effects, some, or none at all. It depends on the type and amount of chemotherapy you get and how your body reacts. Some common side effects are fatigue, nausea, vomiting, pain, and hair loss. There are ways to prevent or control some side effects. Talk with your health care provider about how to manage them. Healthy cells usually recover after chemotherapy is over, so most side effects gradually go away.
Your treatment plan will depend on the cancer type, the chemotherapy drugs used, the treatment goal, and how your body responds. Chemotherapy may be given alone or with other treatments. You may get treatment every day, every week, or every month. You may have breaks between treatments so that your body has a chance to build new healthy cells. You might take the drugs by mouth, in a shot, as a cream, or intravenously (by IV).
NIH: National Cancer Institute
[Learn More]
* Please review the disclaimer below.
